Home › Prostate Cancer › Oklahoma
Prostate Cancer clinical trials in Oklahoma
25 studies for Prostate Cancer are looking for participants at sites in Oklahoma.
Cities in Oklahoma
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Men · Updated Nov 13, 2026 · NCT04423211Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03866382Sacral Neuromodulation for Male Overactive Bladder (MOAB)
- Utica Park Urology, Tulsa
Recruiting
Ages 18 and older · Men · Updated Nov 12, 2026 · NCT06511141The Vanguard Study: Testing a New Way to Screen for Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Nov 6, 2026 · NCT06995898Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Oklahoma City, Oklahoma City
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06632977Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Men · Updated Nov 3, 2026 · NCT07200830Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Men · Updated Nov 3, 2026 · NCT06931340Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 23, 2026 · NCT05946213A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Hightower Clinical, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 20, 2026 · NCT07213674This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- OU Health Medical Center, Oklahoma City
- OU Health Stephenson Cancer Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 14, 2026 · NCT07028853Characterizing the Genomic Landscape of Cancer in Native American Populations (NAT-Geno)
- OU Health Stephenson Cancer Center, Oklahoma City
RecruitingObservational study
Ages 18 to 100 · Men · Updated Oct 13, 2026 · NCT06960798Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 8, 2026 · NCT03678025The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Oklahoma, Oklahoma City
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- Oklahoma Proton Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 29, 2026 · NCT01492972Protoacoustic Imaging For 3D Mapping
- OU Health Stephenson Cancer Center, Oklahoma City
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07832617Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- Urologic Specialists, Tulsa
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 11, 2026 · NCT06056830A Study of DM002 in Patients With Advanced Solid Tumors
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06751329Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Men · Updated Jul 14, 2026 · NCT06592924Using a mHealth App to Improve Quality-of-Life Outcomes in Black Prostate Cancer Survivors
- University of Oklahoma HSC, Oklahoma City
Recruiting
Ages 18 and older · Men · Updated Apr 1, 2026 · NCT06651359Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · Men · Updated Jan 29, 2026 · NCT05806515Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Men · Updated Jan 22, 2026 · NCT06470243Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer
- OU Health Stephenson Cancer Center, Oklahoma City
RecruitingObservational study
Ages 18 and older · All sexes · Updated Dec 17, 2025 · NCT07014618SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Connect2Care: Prostate Cancer Education and Screenings for African American Men
- TSET Health Promotion Research Center, Oklahoma City
Recruiting
Ages 45 to 69 · Men · Updated Sep 25, 2025 · NCT07055165From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.